Trial Profile
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs SBI 087 (Primary) ; SBI 087 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Apr 2016 Results of pooled analysis of two trials (NCT00641225 and NCT00714116) published in the Clinical Therapeutics
- 07 Sep 2012 Planned end date changed from 1 Sep 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.